Atorvastatin derived HMG-CoA reductase degradation inducing compound
US11066391B1 · kind B1 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 24, 2021 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Mar 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to bifunctional compounds that induce HMG-CoA reductase degradation, in which in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked. The present invention also relates to a preparation method of the compounds, a method for degrading HMG-CoA reductase using the compounds, and a composition for the prevention or treatment of HMG-CoA reductase-related diseases comprising the compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.